Nivo: nivolumab; Pemb: pembrolizumab; Ipil: ipilimumab; Atezo: atezolizumab; NSCLC: non- small- cell- lung- cancer; TCC: transitional cell carcinoma; HCC: hepatocellular carcinoma; RCC: renal cell carcinoma; HNSCC: head and neck squamous cell carcinoma; PFS: progression free survival; DCR: disease control rate; ORR:overall response rates; OS: overall survival.